PH12023552425A1 - Hb-egf gene therapy for diabetes - Google Patents
Hb-egf gene therapy for diabetesInfo
- Publication number
- PH12023552425A1 PH12023552425A1 PH1/2023/552425A PH12023552425A PH12023552425A1 PH 12023552425 A1 PH12023552425 A1 PH 12023552425A1 PH 12023552425 A PH12023552425 A PH 12023552425A PH 12023552425 A1 PH12023552425 A1 PH 12023552425A1
- Authority
- PH
- Philippines
- Prior art keywords
- diabetes
- growth factor
- gene therapy
- formulation
- encodes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 title 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000010005 growth-factor like effect Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021033714 | 2021-03-03 | ||
| JP2021145796 | 2021-09-07 | ||
| PCT/JP2022/008898 WO2022186282A1 (ja) | 2021-03-03 | 2022-03-02 | 糖尿病に対するｈｂ－ｅｇｆ遺伝子治療 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023552425A1 true PH12023552425A1 (en) | 2024-02-19 |
Family
ID=83154306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/552425A PH12023552425A1 (en) | 2021-03-03 | 2022-03-02 | Hb-egf gene therapy for diabetes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240173381A1 (https=) |
| EP (1) | EP4302785A4 (https=) |
| JP (1) | JPWO2022186282A1 (https=) |
| KR (1) | KR20240004273A (https=) |
| AU (1) | AU2022230492A1 (https=) |
| BR (1) | BR112023017808A2 (https=) |
| CA (1) | CA3212726A1 (https=) |
| IL (1) | IL305627A (https=) |
| MX (1) | MX2023010315A (https=) |
| PH (1) | PH12023552425A1 (https=) |
| WO (1) | WO2022186282A1 (https=) |
| ZA (1) | ZA202309227B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025211357A1 (https=) * | 2024-04-02 | 2025-10-09 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1949907B1 (en) * | 2005-09-28 | 2014-07-02 | Kagoshima University | Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes |
| JP2007223939A (ja) * | 2006-02-22 | 2007-09-06 | Kobe Univ | エネルギー代謝促進因子としてのｈｂ−ｅｇｆの使用 |
| US8236758B2 (en) * | 2007-07-20 | 2012-08-07 | Saitama Medical University | Method of treatment of diabestes or reduction in pancreatic beta-cells |
| JP6711495B1 (ja) | 2019-05-27 | 2020-06-17 | 株式会社ナイスリー | 車両用盗難防止装置 |
| JP2021033714A (ja) | 2019-08-26 | 2021-03-01 | 東芝テック株式会社 | 商品販売データ処理装置及びプログラム |
| JP7040807B2 (ja) | 2020-03-17 | 2022-03-23 | 株式会社オリンピア | 遊技機 |
-
2022
- 2022-03-02 AU AU2022230492A patent/AU2022230492A1/en active Pending
- 2022-03-02 BR BR112023017808A patent/BR112023017808A2/pt unknown
- 2022-03-02 PH PH1/2023/552425A patent/PH12023552425A1/en unknown
- 2022-03-02 JP JP2023503916A patent/JPWO2022186282A1/ja active Pending
- 2022-03-02 CA CA3212726A patent/CA3212726A1/en active Pending
- 2022-03-02 US US18/548,807 patent/US20240173381A1/en active Pending
- 2022-03-02 KR KR1020237033566A patent/KR20240004273A/ko active Pending
- 2022-03-02 IL IL305627A patent/IL305627A/en unknown
- 2022-03-02 WO PCT/JP2022/008898 patent/WO2022186282A1/ja not_active Ceased
- 2022-03-02 MX MX2023010315A patent/MX2023010315A/es unknown
- 2022-03-02 EP EP22761939.2A patent/EP4302785A4/en active Pending
-
2023
- 2023-10-02 ZA ZA2023/09227A patent/ZA202309227B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4302785A1 (en) | 2024-01-10 |
| CA3212726A1 (en) | 2022-09-09 |
| BR112023017808A2 (pt) | 2023-09-26 |
| JPWO2022186282A1 (https=) | 2022-09-09 |
| KR20240004273A (ko) | 2024-01-11 |
| IL305627A (en) | 2023-11-01 |
| MX2023010315A (es) | 2023-11-24 |
| WO2022186282A1 (ja) | 2022-09-09 |
| US20240173381A1 (en) | 2024-05-30 |
| ZA202309227B (en) | 2024-06-26 |
| EP4302785A4 (en) | 2025-01-29 |
| AU2022230492A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tremblay et al. | A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels | |
| Shi et al. | Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro | |
| Qian et al. | Neural stem cell-derived exosomes transfer miR-124-3p into cells to inhibit glioma growth by targeting FLOT2 | |
| PH12023552425A1 (en) | Hb-egf gene therapy for diabetes | |
| Borhani-Haghighi et al. | The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| IL258164B (en) | Methods for modulating protein and cellular activity and method for nucleic acid synthesis | |
| EP3573618B1 (en) | Compositions and methods for hemoglobin production | |
| ATE556720T1 (de) | Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren | |
| WO2020186207A3 (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
| Cai et al. | Roles of NFκB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization | |
| MX2025015374A (es) | Uso de vectores lentivirales que expresan el factor ix | |
| CO2023016031A2 (es) | Composiciones y métodos para el direccionamiento genético in vivo mediado por nucleasas para el tratamiento de trastornos genéticos | |
| Al‐Khalaf et al. | p16INK4A induces senescence and inhibits EMT through microRNA‐141/microRNA‐146b‐5p‐dependent repression of AUF1 | |
| Kim et al. | Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells | |
| MX2022006949A (es) | Composiciones y metodos para tratar la neuropatia optica hereditaria de leber con proteinas nadh deshidrogenasa. | |
| US20220064642A1 (en) | Oligomeric nucleic acid molecule and application thereof | |
| JOP20230289A1 (ar) | تركيبات توصيل علاج جيني وطرق لعلاج فقد السمع | |
| EP1689872B1 (en) | Promoters for expression in modified vaccinia virus ankara | |
| ES3024480T3 (en) | Regulation of gene expression by aptamer-mediated accessibility of polyadenylation signals | |
| MX2025012045A (es) | Degradador de gspt1 novedoso y su uso | |
| WO2022006551A3 (en) | Modified insulin and glucokinase nucleic acids for treating diabetes | |
| WO2021131944A8 (ja) | 癌遺伝子治療薬 | |
| EP4166157A1 (en) | Composition for treatment of glutaric aciduria and administration method therefor | |
| WO2024015972A3 (en) | Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders in adult patients |